Deutsche Bank’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-56,996
| Closed | -$636K | – | 5329 |
|
|
2017
Q3 | $636K | Sell |
56,996
-253,803
| -82% | -$2.8M | ﹤0.01% | 3289 |
|
|
2017
Q2 | $3.42M | Buy |
310,799
+250,256
| +413% | +$2.5M | ﹤0.01% | 2189 |
|
|
2017
Q1 | $592K | Sell |
60,543
-13,227
| -18% | -$132K | ﹤0.01% | 2983 |
|
|
2016
Q4 | $795K | Sell |
73,770
-49,972
| -40% | -$500K | ﹤0.01% | 2860 |
|
|
2016
Q3 | $1.27M | Buy |
123,742
+18,580
| +18% | +$202K | ﹤0.01% | 2670 |
|
|
2016
Q2 | $1.37M | Sell |
105,162
-15,185
| -13% | -$199K | ﹤0.01% | 2661 |
|
|
2016
Q1 | $1.32M | Buy |
120,347
+94,209
| +360% | +$838K | ﹤0.01% | 2631 |
|
|
2015
Q4 | $239K | Sell |
26,138
-29,023
| -53% | -$243K | ﹤0.01% | 3635 |
|
|
2015
Q3 | $382K | Sell |
55,161
-45,204
| -45% | -$387K | ﹤0.01% | 3510 |
|
|
2015
Q2 | $985K | Buy |
100,365
+40,966
| +69% | +$373K | ﹤0.01% | 2970 |
|
|
2015
Q1 | $525K | Buy |
59,399
+25,927
| +77% | +$207K | ﹤0.01% | 3267 |
|
|
2014
Q4 | $292K | Buy |
33,472
+10,423
| +45% | +$84.4K | ﹤0.01% | 4079 |
|
|
2014
Q3 | $158K | Sell |
23,049
-31,588
| -58% | -$189K | ﹤0.01% | 4223 |
|
|
2014
Q2 | $287K | Buy |
54,637
+13,557
| +33% | +$66K | ﹤0.01% | 3891 |
|
|
2014
Q1 | $186K | Buy |
41,080
+10,549
| +35% | +$51K | ﹤0.01% | 3925 |
|
|
2013
Q4 | $153K | Sell |
30,531
-128,401
| -81% | -$618K | ﹤0.01% | 3831 |
|
|
2013
Q3 | $805K | Buy |
158,932
+84,893
| +115% | +$473K | ﹤0.01% | 3144 |
|
|
2013
Q2 | $367K | Buy |
+74,039
| New | +$352K | ﹤0.01% | 3365 |
|
Deutsche Bank's SCLN Position: Q4 2017 in Review
Deutsche Bank sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 56,996 shares — an estimated $636K sold.
Deutsche Bank first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $3.42M in Q2 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Deutsche Bank reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Deutsche Bank sold 56,996 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $636K.
- Deutsche Bank first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Deutsche Bank's Sciclone Pharmaceuticals Inc position peaked at $3.42M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Deutsche Bank's 13F filing for Q4 2017, filed 14 Feb 2018.